The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ADVL1522: A phase 2 study of IMGN901 (lorvotuzumab mertansine; IND# 126953, NSC# 783609) in children with relapsed or refractory Wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor (MPNST), and synovial sarcoma: A Children's Oncology Group study.
 
James I. Geller
No Relationships to Disclose
 
Joseph Gerald Pressey
No Relationships to Disclose
 
Malcolm A. Smith
No Relationships to Disclose
 
Rachel A. Kudgus
No Relationships to Disclose
 
Renee Schoon
No Relationships to Disclose
 
Renee M. McGovern
No Relationships to Disclose
 
Mariana Cajaiba
No Relationships to Disclose
 
Joel M. Reid
No Relationships to Disclose
 
David Hall
No Relationships to Disclose
 
Donald A. Barkauskas
Patents, Royalties, Other Intellectual Property - U.S. patent based on Ph.D. research in glioblastoma (I)
 
Jeffrey Dome
No Relationships to Disclose
 
Elizabeth Fox
No Relationships to Disclose
 
Brenda Weigel
Travel, Accommodations, Expenses - Genentech; Lilly/ImClone; Nektar; Roche/Genentech; Roche/Genentech